Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort-Reference-Cited by-同舟云学术

Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort

Published:2018-08 Issue:8 Volume:8 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer Journal

Author:

Bohers Elodie^ORCID,Viailly Pierre-Julien,Becker Stéphanie,Marchand Vinciane,Ruminy Philippe,Maingonnat Catherine,Bertrand Philippe,Etancelin Pascaline,Picquenot Jean-Michel,Camus Vincent,Menard Anne-Lise,Lemasle Emilie,Contentin Nathalie,Leprêtre Stéphane,Lenain Pascal,Stamatoullas Aspasia,Lanic Hélène,Libraire Julie,Vaudaux Sandrine,Pepin Louis-Ferdinand,Vera Pierre,Tilly Hervé,Jardin Fabrice

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/s41408-018-0111-6.pdf

Reference28 articles.

1. Diaz, L. A. & Bardelli, A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 32, 579–586 (2014).

2. Lowes, L. E. et al. Circulating tumor cells (CTC) and cell-free DNA (cfDNA) workshop 2016: scientific opportunities and logistics for cancer clinical trial incorporation. Int. J. Mol. Sci. 17, E1505 (2016).

3. Alizadeh, A. A. et al. Toward understanding and exploiting tumor heterogeneity. Nat. Med. 21, 846–853 (2015).

4. Wang, C. et al. A panel of five serum miRNAs as a potential diagnostic tool for early-stage renal cell carcinoma. Sci. Rep. 5, 7610 (2015).

5. Anker, P., Lyautey, J., Lederrey, C. & Stroun, M. Circulating nucleic acids in plasma or serum. Clin. Chim. Acta 313, 143–146 (2001).

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Minimal residual disease detection in lymphoma: methods, procedures and clinical significance;Frontiers in Immunology;2024-08-12

2. Liquid biopsy for molecular characterization of diffuse large B‐cell lymphoma and early assessment of minimal residual disease;British Journal of Haematology;2024-05-29

3. Circulating Tumor DNA as a Complementary Prognostic Biomarker during CAR-T Therapy in B-Cell Non-Hodgkin Lymphomas;Cancers;2024-05-15

4. Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?;Current Treatment Options in Oncology;2024-04-24

5. Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy;Journal for ImmunoTherapy of Cancer;2024-03